Michael J Donovan, PhD, MD
- RESEARCH PROFESSOR | Pathology, Molecular and Cell Based Medicine
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Donovan during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Exosome Diagnostics, Inc.; LungLifeAI; PreciseDx
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
Service on Board of Directors: Service in a fiduciary capacity, such as an officer or director, for the following companies:
- LungLifeAI; PreciseDx; RenalytixAI; Verici Dx
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.